189 related articles for article (PubMed ID: 30309697)
1. Usefulness of compounds with monacolin K in a case of statins intolerance.
Parra-Virto A; Torres do Rego A; Demelo-Rodríguez P; Millán Núñez-Cortés J; Álvarez-Sala LA
Clin Investig Arterioscler; 2018; 30(6):268-270. PubMed ID: 30309697
[TBL] [Abstract][Full Text] [Related]
2. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
[TBL] [Abstract][Full Text] [Related]
3. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
4. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.
Stefanutti C; Mazza F; Mesce D; Morozzi C; Di Giacomo S; Vitale M; Pergolini M
Atheroscler Suppl; 2017 Nov; 30():86-91. PubMed ID: 29096866
[TBL] [Abstract][Full Text] [Related]
5. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
6. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Miyoshi T; Nakamura K; Doi M; Ito H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
[TBL] [Abstract][Full Text] [Related]
7. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
8. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
9. Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy.
Rallidis LS; Triantafyllis AS; Iliodromitis E
Hellenic J Cardiol; 2018; 59(5):293-295. PubMed ID: 29128548
[No Abstract] [Full Text] [Related]
10. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
Ruel I; Aljenedil S; Sadri I; de Varennes É; Hegele RA; Couture P; Bergeron J; Wanneh E; Baass A; Dufour R; Gaudet D; Brisson D; Brunham LR; Francis GA; Cermakova L; Brophy JM; Ryomoto A; Mancini GBJ; Genest J
Clin Chem; 2018 Feb; 64(2):355-362. PubMed ID: 29038147
[TBL] [Abstract][Full Text] [Related]
11. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.
Pisciotta L; Fasano T; Bellocchio A; Bocchi L; Sallo R; Fresa R; Colangeli I; Cantafora A; Calandra S; Bertolini S
Atherosclerosis; 2007 Oct; 194(2):e116-22. PubMed ID: 17140581
[TBL] [Abstract][Full Text] [Related]
12. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
14. [Red yeast rice, monacolin K, and pleiotropic effects.].
Cicero AFG
Recenti Prog Med; 2018 Feb; 109(2):154e-157e. PubMed ID: 29493648
[TBL] [Abstract][Full Text] [Related]
15. [Unmet needs: patients with statin intolerance or familial hypercholesterolemia].
Masana L; Civeira F
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():22-30. PubMed ID: 27888902
[TBL] [Abstract][Full Text] [Related]
16. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors.
Marco-Benedí V; Jarauta E; Pérez-Calahorra S; Bea AM; Civeira F
Clin Investig Arterioscler; 2019; 31(2):89-92. PubMed ID: 30738610
[TBL] [Abstract][Full Text] [Related]
17. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
18. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
Ortega Martínez de Victoria E
Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
[No Abstract] [Full Text] [Related]
20. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
